Bristol Myers Squibb

Bristol Myers Squibb Operating Metrics

Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.

Bristol Myers Squibb key operating metrics including Research and Development Centers, environmental, and social and governance score (ESG).

Research and Development Centers

8.3%

FY, 2021

Phase II Trials Products (Oncology)

15.4%

FY, 2021

Phase III Trials Products (Oncology)

16.7%

FY, 2021

Operating Metrics

Metrics	FY, 2018	FY, 2019	FY, 2020	FY, 2021
Research and Development Centers	7	12	12	11
Phase II Trials Products (Oncology)	9	14	13	15
Phase III Trials Products (Oncology)	8	9	6	7
Phase I Trials Products (Immunology)	5	5	9	6
Phase II Trials Products (Immunology)	2	4	4	6
Phase III Trials Products (Immunology)	3	4	4	3
Phase I Trials Products (Cardiovascular)	2	3	3	3
Phase I Trials Products (Oncology)	15	19	22	20
Phase II Trials Products (Cardiovascular)	3	3	5	5
Phase I Trials Products (Fibrotic Diseases)	1	1	2	1
Phase II Trials Products (Fibrotic Diseases)	2	3	4	2
Phase III Trials Products (Cardiovascular)	1		2
Manufacturing Facilities	7	7	7	8
Phase III Trials Products (Hematology)		10	9	7
Phase II Trials Products (Hematology)		8	8	9
Phase I Trials Products (Hematology)		14	23	20
Phase I Trials Products (COVID-19)			1
Phase I Trials Products (Neuroscience)			1	4
Phase II Trials Products (COVID-19)				2

60-79 out of 100

Community

Employees

Environment

Governance

Premium Content only available in Craft’s Intelligence Portal

Source:CSRHub